GNLX

SEC source: 0001415889-24-016107 · form4-06072024_090604.xml · nonDerivative · entry 1

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,460

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016101 · form4-06072024_090610.xml · derivative · entry 2

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2029-05-29

F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs.

F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016101 · form4-06072024_090610.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs.

F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016100 · form4-06072024_090608.xml · derivative · entry 3

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-05-29

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

F2 · ownership.nature: By Zindrick Living Trust DTD 3-5-2009

SEC source: 0001415889-24-016100 · form4-06072024_090608.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,000

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

F2 · ownership.nature: By Zindrick Living Trust DTD 3-5-2009

SEC source: 0001415889-24-016099 · form4-06072024_090606.xml · derivative · entry 2

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2029-05-29

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016099 · form4-06072024_090606.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,315

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016098 · form4-06072024_090603.xml · derivative · entry 2

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-05-29

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016098 · form4-06072024_090603.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,572

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016097 · form4-06072024_090601.xml · derivative · entry 2

Zak Lourie S. · CIK 0001991207 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2029-05-29

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-016097 · form4-06072024_090601.xml · nonDerivative · entry 1

Zak Lourie S. · CIK 0001991207 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,250

F1 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00.

SEC source: 0001415889-24-013263 · form4-05152024_090533.xml · nonDerivative · entry 3

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,139,821

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-013263 · form4-05152024_090533.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,156,915

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.945, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-013263 · form4-05152024_090533.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,172,341

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-012744 · form4-05092024_080522.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,175,787

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-012744 · form4-05092024_080522.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,189,706

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.595 to $3.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011901 · form4-05012024_100551.xml · nonDerivative · entry 3

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,195,731

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-24-011901 · form4-05012024_100551.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,228,792

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011901 · form4-05012024_100551.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,249,327

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.16 to $3.355, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011460 · form4-04242024_090454.xml · nonDerivative · entry 3

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,255,730

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011460 · form4-04242024_090454.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,263,794

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.515, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011460 · form4-04242024_090454.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,285,794

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.33 to $3.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011137 · form4-04182024_090450.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,300,125

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.615 to $3.765, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-011137 · form4-04182024_090450.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,322,862

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.5695, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001415889-24-019344 · form4-07082024_040711.xml · nonDerivative · entry 2

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,953

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

SEC source: 0001415889-24-019347 · form4-07082024_040717.xml · nonDerivative · entry 2

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,207

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

F3 · balance_after: Includes 972 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2024.

SEC source: 0001415889-24-019346 · form4-07082024_040715.xml · nonDerivative · entry 2

Zak Lourie S. · CIK 0001991207 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,428

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

F3 · balance_after: Includes 2,106 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2024.

SEC source: 0001415889-24-019345 · form4-07082024_040713.xml · nonDerivative · entry 2

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,144

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

F3 · balance_after: Includes 2,106 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2024.

SEC source: 0001415889-24-019343 · form4-07082024_040709.xml · nonDerivative · entry 2

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,718

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

SEC source: 0001415889-24-019342 · form4-07082024_040707.xml · nonDerivative · entry 2

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,778

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

SEC source: 0001415889-24-019341 · form4-07082024_040703.xml · nonDerivative · entry 2

Jewett Caroline · CIK 0001983187 · Head of Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,890

F2 · kind: Represents RSUs that are fully vested as of March 14, 2024.

SEC source: 0001415889-24-019344 · form4-07082024_040711.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,396

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019347 · form4-07082024_040717.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,971

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019346 · form4-07082024_040715.xml · nonDerivative · entry 1

Zak Lourie S. · CIK 0001991207 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,470

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019345 · form4-07082024_040713.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,931

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019343 · form4-07082024_040709.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,161

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019342 · form4-07082024_040707.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,508

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001415889-24-019341 · form4-07082024_040703.xml · nonDerivative · entry 1

Jewett Caroline · CIK 0001983187 · Head of Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,278

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.

SEC source: 0001209191-23-058954 · doc4.xml · nonDerivative · entry 2

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The weighted average sale price for the transaction reported was $14.1763, and the range of prices were between $13.80 and $14.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-058954 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,803

F1 · price: The weighted average sale price for the transaction reported was $12.9401, and the range of prices were between $12.69 and $13.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-058710 · doc4.xml · nonDerivative · entry 2

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,460

F2 · price: The weighted average sale price for the transaction reported was $13.7327, and the range of prices were between $13.33 and $14.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-058710 · doc4.xml · nonDerivative · entry 1

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,807

F1 · price: The weighted average sale price for the transaction reported was $12.9145, and the range of prices were between $12.29 and $13.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-058709 · doc4.xml · nonDerivative · entry 2

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 463,460

F2 · price: The weighted average sale price for the transaction reported was $13.9277, and the range of prices were between $13.80 and $14.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-058709 · doc4.xml · nonDerivative · entry 1

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 465,387

F1 · price: The weighted average sale price for the transaction reported was $13.2261, and the range of prices were between $12.76 and $13.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-057975 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,535

F1 · price: The weighted average sale price for the transaction reported was $11.8477, and the range of prices were between $11.51 and $12.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-056455 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,335

F1 · price: The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-056237 · doc4.xml · nonDerivative · entry 2

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,000

F2 · price: The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-056237 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,594

F1 · price: The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-053676 · doc4.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,371,545

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: Shares held by The Szalay 2010 Retained Annuity Trust.

SEC source: 0001209191-23-053554 · doc4.xml · derivative · entry 3

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,653

Underlying: Common Stock · 5,200 shares

Expires 2029-09-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.